CCL2 and neoplasm: Moreover, cytokine-driven activation of the CCL2/AKT/β-catenin axis by TAMs further potentiates CSC maintenance and tumor aggressiveness, ultimately fostering TNBC progression and resistance to therapy (60) (Figure 1).